99115-96-5Relevant academic research and scientific papers
MITRAGYNINE ALKALOIDS AS OPIOID RECEPTOR MODULATORS
-
Page/Page column 67; 71, (2017/10/13)
The present invention provides a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with pain, a depressive disorder, a mood disorder or an anxiety disorder by administering the compound to the subject.
Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators
Kruegel, Andrew C.,Gassaway, Madalee M.,Kapoor, Abhijeet,Váradi, András,Majumdar, Susruta,Filizola, Marta,Javitch, Jonathan A.,Sames, Dalibor
supporting information, p. 6754 - 6764 (2016/06/14)
Mu-opioid receptor agonists represent mainstays of pain management. However, the therapeutic use of these agents is associated with serious side effects, including potentially lethal respiratory depression. Accordingly, there is a longstanding interest in the development of new opioid analgesics with improved therapeutic profiles. The alkaloids of the Southeast Asian plant Mitragyna speciosa, represented by the prototypical member mitragynine, are an unusual class of opioid receptor modulators with distinct pharmacological properties. Here we describe the first receptor-level functional characterization of mitragynine and related natural alkaloids at the human mu-, kappa-, and delta-opioid receptors. These results show that mitragynine and the oxidized analogue 7-hydroxymitragynine, are partial agonists of the human mu-opioid receptor and competitive antagonists at the kappa- and delta-opioid receptors. We also show that mitragynine and 7-hydroxymitragynine are G-protein-biased agonists of the mu-opioid receptor, which do not recruit β-arrestin following receptor activation. Therefore, the Mitragyna alkaloid scaffold represents a novel framework for the development of functionally biased opioid modulators, which may exhibit improved therapeutic profiles. Also presented is an enantioselective total synthesis of both (-)-mitragynine and its unnatural enantiomer, (+)-mitragynine, employing a proline-catalyzed Mannich-Michael reaction sequence as the key transformation. Pharmacological evaluation of (+)-mitragynine revealed its much weaker opioid activity. Likewise, the intermediates and chemical transformations developed in the total synthesis allowed the elucidation of previously unexplored structure-activity relationships (SAR) within the Mitragyna scaffold. Molecular docking studies, in combination with the observed chemical SAR, suggest that Mitragyna alkaloids adopt a binding pose at the mu-opioid receptor that is distinct from that of classical opioids.
SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS
-
Page/Page column 25, (2008/06/13)
This invention concerns sulfonylpyrazoline carboxamidine derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes. The compounds have the general formula (1), wherein the symbols have the meanings given in the description.
Porphyrins with exocyclic rings. Part 12. Synthesis of meso,β-butano- and meso,β-pentanoporphyrins from cycloalka[b]pyrroles
Bastian, Jolie A.,Lash, Timothy D.
, p. 6299 - 6310 (2007/10/03)
Pyrroles 5 with b-face fused seven- or eight-membered carbocyclic rings were prepared in good yields by Knorr-type condensations with cycloheptanone or cyclooctanone, respectively. Treatment with lead tetraacetate in dichloromethane afforded the labile ω-acetates 8 and subsequent acid catalyzed condensation with α-unsubstituted pyrrole-2-carboxylates yielded the related pyrrolylcycloalka[b]pyrroles 29 and 30. The α-unsubstituted pyrroles 14 and 23 were prepared by condensing α,β-unsubstituted ketones, or their β-acetoxycarbonyl precursors, with benzyl N-tosylglycinate in the presence of DBU, followed by dehydration with POCl3-pyridine and base catalyzed elimination of p-toluenesulfinic acid. Dipyrrole dibenzyl esters 29 and 30 were hydrogenolysed over 10% Pd-C to give the corresponding dicarboxylic acids. Acid catalyzed condensation with diformyldipyrrylmethane 33 under modified MacDonald '2 + 2' conditions afforded a series of four cycloalkanoporphyrins 4a-d with seven- or eight-membered exocyclic rings. Although the meso,β-butanoporphyrins 4a and 4b were isolated in good yields, poorer results were obtained for the related meso,β-pentanoporphyrin: 4c and 4d. It is proposed that the eight-membered carbocyclic ring distorts the geometry of the open-chain tetrapyrrolic intermediates and this deleterious influence results in the lower yields observed.
